Boston Scientific Corporation (BSX) Guidance & Earnings Results

On 2026-07-29 Boston Scientific Corporation raised guidance: "FY2026 net sales growth guidance raised to approximately 7.5-8.5% reported (from prior 6.5-7.5%); Q3 2026 net sales growth guidance 6.5-8.5% reported; adjusted EPS guidance raised to $3.45-3.50 (from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BSXBoston Scientific CorporationFollow BSX — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 66.2B
P/E TTM: 18.5
Dividend yield: —
52-week: —
Next earnings: 28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Raised	FY2026 net sales growth guidance raised to approximately 7.5-8.5% reported (from prior 6.5-7.5%); Q3 2026 net sales growth guidance 6.5-8.5% reported; adjusted EPS guidance raised to $3.45-3.50 (from $3.35-3.42) · full year
22 Apr 26	Raised	Net sales guidance 10.5-12.0% reported, 8.5-10.0% operational/organic; actual 11.6% and 9.4% respectively
22 Oct 25	Raised	Reported net sales guidance 17-19% vs actual 20.3%; organic guidance 12-14% vs actual 15.3%; GAAP EPS guidance $0.44-$0.46 vs actual $0.51; adjusted EPS guidance $0.70-$0.72 vs actual $0.75

Boston Scientific Corporation — questions

What guidance did Boston Scientific Corporation give?: On 2026-07-29: "FY2026 net sales growth guidance raised to approximately 7.5-8.5% reported (from prior 6.5-7.5%); Q3 2026 net sales growth guidance 6.5-8.5% reported; adjusted EPS guidance raised to $3.45-3.50 (from $3.35-3.42)"
When does Boston Scientific Corporation report earnings?: Boston Scientific Corporation's next earnings report is expected on 2026-10-28.

Every figure on this page comes from Boston Scientific Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.